Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Jefferson Research

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Meridian Bioscience Inc Reaffirmed FY 2013 Guidance

Thursday, 8 Nov 2012 07:30am EST 

Meridian Bioscience Inc announced that for fiscal 2013, it expects net sales to be in the range of $190-$195 million and per share diluted earnings to be between $0.86-$0.91. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $189 million and EPS of $0.88 for fiscal 2013. 

Company Quote

-0.47 -2.51%
4:00pm EDT